TD2 - THE TRANSLATIONAL ONCOLOGY CRO Trademark

Trademark Overview

On Wednesday, June 28, 2017, a trademark application was filed for TD2 - THE TRANSLATIONAL ONCOLOGY CRO with the United States Patent and Trademark Office. The USPTO has given the TD2 - THE TRANSLATIONAL ONCOLOGY CRO trademark a serial number of 87509079. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 22, 2021. This trademark is owned by TRANSLATIONAL DRUG DEVELOPMENT, LLC. The TD2 - THE TRANSLATIONAL ONCOLOGY CRO trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Consulting services for others in the field of design, planning, and implementation of project management for scientific research, clinical trials, and statistical analyses in the field of oncology; Scientific research, namely, conducting pre-clinical trials and supporting clinical trials for others; Providing scientific research information in the field of pre-clinical testing; Pharmaceutical drug development and related services, namely, pharmaceutical products development and pharmaceutical research services
td2 - the translational oncology cro

General Information

Serial Number87509079
Word MarkTD2 - THE TRANSLATIONAL ONCOLOGY CRO
Filing DateWednesday, June 28, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, February 22, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 21, 2017

Trademark Statements

Disclaimer with Predetermined Text"TRANSLATIONAL ONCOLOGY CRO"
Goods and ServicesConsulting services for others in the field of design, planning, and implementation of project management for scientific research, clinical trials, and statistical analyses in the field of oncology; Scientific research, namely, conducting pre-clinical trials and supporting clinical trials for others; Providing scientific research information in the field of pre-clinical testing; Pharmaceutical drug development and related services, namely, pharmaceutical products development and pharmaceutical research services
Pseudo MarkTRANSLATIONAL DRUG DEVELOPMENT TWO - THE TRANSLATIONAL ONCOLOGY CRO

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, July 6, 2017
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTRANSLATIONAL DRUG DEVELOPMENT, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressScottsdale, AZ 85259
Party NameTRANSLATIONAL DRUG DEVELOPMENT, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressScottsdale, AZ 85259

Trademark Events

Event DateEvent Description
Monday, February 22, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, February 22, 2021ABANDONMENT - NO USE STATEMENT FILED
Tuesday, July 21, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 20, 2020EXTENSION 5 GRANTED
Thursday, July 16, 2020EXTENSION 5 FILED
Thursday, July 16, 2020TEAS EXTENSION RECEIVED
Friday, January 17, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 15, 2020EXTENSION 4 GRANTED
Wednesday, January 15, 2020EXTENSION 4 FILED
Wednesday, January 15, 2020TEAS EXTENSION RECEIVED
Wednesday, September 25, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 24, 2019EXTENSION 3 GRANTED
Tuesday, July 16, 2019EXTENSION 3 FILED
Tuesday, September 24, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, July 31, 2019NOTICE OF REVIVAL - E-MAILED
Tuesday, July 30, 2019EXTENSION RECEIVED WITH TEAS PETITION
Tuesday, July 30, 2019PETITION TO REVIVE-GRANTED
Tuesday, July 30, 2019TEAS PETITION TO REVIVE RECEIVED
Thursday, January 17, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 15, 2019EXTENSION 2 GRANTED
Tuesday, January 15, 2019EXTENSION 2 FILED
Tuesday, January 15, 2019TEAS EXTENSION RECEIVED
Wednesday, July 18, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 16, 2018EXTENSION 1 GRANTED
Monday, July 16, 2018EXTENSION 1 FILED
Monday, July 16, 2018TEAS EXTENSION RECEIVED
Tuesday, January 16, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 21, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 21, 2017PUBLISHED FOR OPPOSITION
Wednesday, November 1, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, October 13, 2017LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, October 12, 2017ASSIGNED TO LIE
Friday, September 29, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, September 28, 2017EXAMINER'S AMENDMENT ENTERED
Thursday, September 28, 2017NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, September 28, 2017EXAMINERS AMENDMENT E-MAILED
Thursday, September 28, 2017EXAMINERS AMENDMENT -WRITTEN
Monday, September 25, 2017ASSIGNED TO EXAMINER
Thursday, July 6, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, July 1, 2017NEW APPLICATION ENTERED IN TRAM

Related Keywords

oncology translational research clinical trials scientific pharmaceutical services field namely development others